These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 24914740)

  • 1. A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants.
    Carrier M; Kimpton M; Wells PS; Langlois N; Kherani S; Le Gal G
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):812-5. PubMed ID: 24914740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study.
    Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM
    Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the time in therapeutic range using the ratio of tests equivalent to the Rosendaal method?
    Caldeira D; Cruz I; Morgado G; Stuart B; Gomes AC; Martins C; João I; Pereira H
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):972-6. PubMed ID: 26083988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining time in therapeutic range for busy clinicians: frequency of dose changes is a good surrogate marker to identify patients with suboptimal anticoagulation with warfarin.
    Vijenthira A; Le Gal G; Castellucci LA; Carrier M
    Thromb Res; 2014 Sep; 134(3):584-6. PubMed ID: 25037497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
    Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H
    Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study.
    Caldeira D; Cruz I; Morgado G; Stuart B; Gomes C; Martins C; João I; Pereira H
    BMC Res Notes; 2014 Dec; 7():891. PubMed ID: 25491419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.
    Barco S; Granziera S; Coppens M; Douxfils J; Nijkeuter M; Riva N; Vanassche T; Zhang G; Lin M; Kamphuisen PW; Cohen AT; Beyer-Westendorf J
    Thromb Haemost; 2019 Apr; 119(4):675-684. PubMed ID: 30731492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in a cohort of patients with venous thromboembolism treated with vitamin K antagonists.
    Demelo-Rodríguez P; Postigo-Esteban A; García-Fernández-Bravo I; Agud M; Calpena S; Camacho M; Del Toro-Cervera J
    Thromb Res; 2016 Nov; 147():58-60. PubMed ID: 27676254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry.
    Le Heuzey JY; Ammentorp B; Darius H; De Caterina R; Schilling RJ; Schmitt J; Zamorano JL; Kirchhof P
    Thromb Haemost; 2014 May; 111(5):833-41. PubMed ID: 24651882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
    Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA;
    J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients.
    Kooistra HA; Veeger NJ; Khorsand N; Kluin-Nelemans HC; Meijer K; Piersma-Wichers M
    Thromb Haemost; 2015 Apr; 113(4):881-90. PubMed ID: 25518854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study using thrombin generation and three different INR methods in patients on Vitamin K antagonist treatment.
    Riva N; Vella K; Meli S; Hickey K; Zammit D; Calamatta C; Makris M; Kitchen S; Ageno W; Gatt A
    Int J Lab Hematol; 2017 Oct; 39(5):482-488. PubMed ID: 28500649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study.
    Palareti G; Antonucci E; Lip GY; Testa S; Guazzaloca G; Falanga A; Pengo V; Poli D;
    Thromb Haemost; 2016 Jun; 115(6):1101-8. PubMed ID: 26819229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
    Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
    Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa.
    Mwita JC; Francis JM; Pillay C; Ogah OS; Goshu DY; Agyekum F; Musonda JM; James MC; Tefera E; Kabo T; Ditlhabolo KI; Ndlovu K; Ayodele AY; Mikomangwa WP; Chillo P; Damasceno A; Folson AA; Oyekunle A; Tebuka E; Kalokola F; Forrest K; Dunn H; Karaye K; Jean-Pierre FL; Oljira CF; Assefa T; Taiwo TS; Nwafor CE; Omole O; Anakwue R; Cohen K
    J Thromb Thrombolysis; 2024 Apr; 57(4):613-621. PubMed ID: 38478250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction Score for Anticoagulation Control Quality Among Older Adults.
    Lin KJ; Singer DE; Glynn RJ; Blackley S; Zhou L; Liu J; Dube G; Oertel LB; Schneeweiss S
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28982676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
    Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation control and cost of monitoring of older patients on chronic warfarin therapy in three settings in North East England.
    Abohelaika S; Kamali F; Avery P; Robinson B; Kesteven P; Wynne H
    Age Ageing; 2014 Sep; 43(5):708-11. PubMed ID: 24947831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.